Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes

Haematologica. 2010 Aug;95(8):1433-4. doi: 10.3324/haematol.2010.024992. Epub 2010 Apr 26.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Benzoates / administration & dosage
  • Benzoates / therapeutic use*
  • Biomarkers / blood
  • Deferasirox
  • Female
  • Ferritins / blood
  • Humans
  • Iron / blood
  • Iron Chelating Agents / administration & dosage
  • Iron Chelating Agents / therapeutic use
  • Iron Overload / blood
  • Iron Overload / drug therapy*
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / blood
  • Myelodysplastic Syndromes / drug therapy*
  • Oxidative Stress / drug effects*
  • Time Factors
  • Treatment Outcome
  • Triazoles / administration & dosage
  • Triazoles / therapeutic use*

Substances

  • Benzoates
  • Biomarkers
  • Iron Chelating Agents
  • Triazoles
  • Ferritins
  • Iron
  • Deferasirox

Associated data

  • ClinicalTrials.gov/NCT00452660